PierianDx is a leading clinical genomics informatics company that empowers progressive health institutions and diagnostic laboratories to build world-class precision medicine programs.
PierianDx is catalyzing global adoption of genomic sequencing in healthcare by empowering physicians in the laboratory and clinic to more effectively diagnose and treat patients with cancer and other complex diseases.
PierianDx was founded in 2014 by Rakesh Nagarajan and is headquartered in Saint Louis, Missouri.
PierianDx is focused on advancing cancer diagnostics and making targeted therapeutics more accessible to healthcare systems, laboratories, and patients worldwide.
PierianDx’s industry-leading genomic SaaS solutions, CAP and CLIA accredited laboratory, and shared knowledgebase are used by health systems, cancer centers and commercial laboratories worldwide driving the most integrated approach across the clinical care spectrum.
PierianDx is backed by ATW Partners, SJF Ventures, Health Catalyst Capital, RTI International, Inova Health Systems and others. The company raised $27M from a "Series B" financing on Oct 28, 2019. This new round brings PierianDx's total funding to $47M to date.